Edwards Lifesciences Corporation (EW) Q2 2017 Earnings Results

Edwards Lifesciences Beats on EPS, Stock Down 0.22%

Edwards Lifesciences reported a strong EPS performance, beating expectations by nearly 19%. However, the stock reacted negatively, declining slightly by 0.22%. The lack of revenue figures and future guidance may have contributed to investor caution.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$1.08	N/A	+18.95%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Overall, management conveyed a sense of confidence in their operational strategies. However, they did not provide specific guidance for future quarters.

Management expressed satisfaction with the EPS performance despite not providing revenue figures.

They highlighted ongoing investments in innovation and product development.

Edwards Lifesciences Beats on EPS, Stock Down 0.22%

Key numbers

Management commentary

Edwards Lifesciences Corporation

More earnings this week

Edwards Lifesciences Beats on EPS, Stock Down 0.22%

Key numbers

Management commentary